Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ACRS

Aclaris Therapeutics Inc

Dec 11 • 04:00PM ET

3.54

Dollar change -0.09
Percentage change -2.48	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: NBIX PCRX AGIO SRPT BMRN ALKS ENTA FGEN VKTX XERS

| Held by: VTI VXF IBB IWC VHT ONEQ DFAS BIB IBBQ DFUS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.52	Insider Own	16.15%	Shs Outstand	71.42M	Perf Week	-5.85%
Market Cap	252.87M	Forward P/E	-	EPS next Y	-0.52	Insider Trans	91.78%	Shs Float	59.89M	Perf Month	34.60%
Income	-37.00M	PEG	-	EPS next Q	-0.25	Inst Own	75.64%	Short Float	4.14%	Perf Quarter	202.56%
Sales	27.08M	P/S	9.34	EPS this Y	41.73%	Inst Trans	52.36%	Short Ratio	1.11	Perf Half Y	207.83%
Book/sh	1.82	P/B	1.94	EPS next Y	29.73%	ROA	-18.47%	Short Interest	2.48M	Perf Year	263.82%
Cash/sh	1.79	P/C	1.98	EPS next 5Y	-	ROE	-25.83%	52W Range	0.80 - 5.17	Perf YTD	237.14%
Dividend Est.	-	P/FCF	-	EPS past 5Y	20.67%	ROI	-27.95%	52W High	-31.53%	Beta	0.47
Dividend TTM	-	Quick Ratio	7.03	Sales past 5Y	74.29%	Gross Margin	53.53%	52W Low	342.50%	ATR (14)	0.39
Dividend Ex-Date	-	Current Ratio	7.03	EPS Y/Y TTM	68.83%	Oper. Margin	-208.45%	RSI (14)	54.54	Volatility	7.84% 14.23%
Employees	91	Debt/Eq	0.02	Sales Y/Y TTM	26.35%	Profit Margin	-136.65%	Recom	1.57	Target Price	7.60
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	74.27%	Payout	-	Rel Volume	0.37	Prev Close	3.63
Sales Surprise	175.94%	EPS Surprise	-1829.82%	Sales Q/Q	-53.18%	Earnings	Nov 06 BMO	Avg Volume	2.24M	Price	3.54
SMA20	-2.19%	SMA50	47.10%	SMA200	135.13%	Trades		Volume	829,272	Change	-2.48%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-24	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-19-24	Upgrade	Leerink Partners	Market Perform → Outperform	$2 → $7
Nov-19-24	Upgrade	Jefferies	Hold → Buy	$2 → $7
Nov-19-24	Upgrade	BTIG Research	Neutral → Buy	$8
Nov-18-24	Upgrade	Piper Sandler	Neutral → Overweight	$3 → $13
Jan-22-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-13-23	Downgrade	William Blair	Outperform → Mkt Perform
Oct-03-23	Initiated	Evercore ISI	Outperform	$22
Dec-14-22	Initiated	Stifel	Buy	$29
Dec-01-22	Initiated	Goldman	Buy	$25
Oct-06-22	Initiated	BTIG Research	Buy	$32
Jul-23-21	Resumed	Jefferies	Buy	$27 → $32
Jun-15-21	Initiated	Piper Sandler	Overweight	$30
Apr-21-21	Initiated	H.C. Wainwright	Buy	$40
Oct-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-06-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-27-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-06-19	Initiated	SVB Leerink	Outperform	$13
Mar-28-18	Resumed	Leerink Partners	Outperform	$52
Feb-09-18	Initiated	Guggenheim	Buy	$53

Show Previous Ratings

Dec-03-24 04:30PM	Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-26-24 04:30PM	Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) -9.02% +5.23%
Nov-20-24 05:11AM	Aclaris Therapeutics upgraded to Buy from Hold at Jefferies (TipRanks) -13.73%
Nov-19-24 09:30PM	Aclaris Therapeutics upgraded to Buy from Neutral at BTIG (TipRanks) +46.18%
03:27PM	Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments (Benzinga)
11:00AM	Loading…
11:00AM	Aclaris Therapeutics secures global rights to Biosions antibodies (Pharmaceutical Technology)
Nov-18-24 08:50AM	Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets (PR Newswire) +53.17%
08:10AM	Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline (GlobeNewswire)
08:10AM	Aclaris Therapeutics Announces $80 Million Private Placement (GlobeNewswire)
Nov-06-24 08:05AM	Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:07AM	Aclaris: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Oct-09-24 07:02PM	Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc (GuruFocus.com)
Sep-18-24 06:52AM	Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial (Clinical Trials Arena)
Sep-17-24 07:00AM	Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis (GlobeNewswire)
07:00AM	Loading…
Sep-10-24 07:00AM	Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-07-24 08:15AM	Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:20AM	Aclaris: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-25-24 09:40AM	Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year? (Zacks)
Jul-16-24 04:01PM	Aclaris Therapeutics Announces Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million (GlobeNewswire)
Jul-02-24 01:27PM	Hedge Fund and Insider Trading News: Bill Ackman, David Einhorn, Saba Capital Management, Segantii Capital Management, Two Sigma Advisors, Falcon Investment Management, Aclaris Therapeutics Inc (ACRS), GigaCloud Technology Inc (GCT), and More (Insider Monkey)
Jun-06-24 07:00AM	Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-08-24 12:06PM	Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript (Insider Monkey) -8.96%
07:43AM	Q1 2024 Aclaris Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
04:06AM	Aclaris Therapeutics Inc (ACRS) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... (GuruFocus.com)
May-07-24 10:56PM	ACRS Stock Earnings: Aclaris Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:15PM	Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:11PM	Aclaris: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
07:00AM	Loading…
Apr-30-24 07:00AM	Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update (GlobeNewswire)
Apr-23-24 08:00AM	Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer (PR Newswire)
Apr-05-24 09:40AM	Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year? (Zacks)
Mar-20-24 09:40AM	Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-14-24 08:45AM	Biotech's Role in Addressing the Pancreatic Cancer Emergency (PR Newswire) -8.00%
Mar-04-24 12:00PM	Aclaris (ACRS) Upgraded to Buy: Here's Why (Zacks)
09:40AM	Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year? (Zacks)
Feb-27-24 09:35AM	Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:38AM	Aclaris: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-15-24 10:00AM	Will Aclaris Therapeutics (ACRS) Report Negative Q4 Earnings? What You Should Know (Zacks)
Feb-13-24 09:40AM	Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year? (Zacks)
Jan-17-24 11:14AM	Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO (Zacks)
Jan-16-24 07:00AM	Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review (GlobeNewswire) +25.54%
Jan-10-24 07:00AM	Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis (GlobeNewswire) -21.48%
Jan-04-24 09:40AM	Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year? (Zacks)
Dec-19-23 04:01PM	Aclaris Therapeutics Provides Corporate Update (GlobeNewswire) +8.78% -8.33%
Dec-05-23 04:01PM	Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia (GlobeNewswire)
Dec-04-23 09:35AM	Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +8.74%
Nov-16-23 09:35AM	Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS) (Zacks) +10.42%
Nov-14-23 10:57AM	Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study (Zacks) +5.46%
Nov-13-23 07:17AM	UPDATE 1-Aclaris Therapeutics to stop development of rheumatoid arthritis drug (Reuters) -86.44%
07:06AM	Aclaris Therapeutics to stop development of rheumatoid arthritis drug (Reuters)
07:00AM	Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update (GlobeNewswire)
Nov-06-23 08:03AM	Aclaris Therapeutics Inc (ACRS) Reports Q3 2023 Financial Results (GuruFocus.com)
07:06AM	Aclaris: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Oct-03-23 07:00AM	Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202) (GlobeNewswire)
Sep-20-23 07:00AM	Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire) -8.51%
Sep-18-23 07:00AM	Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor (GlobeNewswire)
Sep-14-23 07:03PM	Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday (Motley Fool) +5.54% -5.62%
Sep-08-23 05:06PM	Insider Buying: CFO Kevin Balthaser Acquires 9,490 Shares of Aclaris Therapeutics Inc (GuruFocus.com)
Aug-10-23 06:07AM	Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.)
Aug-08-23 08:40AM	Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analysts Just Slashed This Year's Revenue Estimates By 11% (Simply Wall St.) -5.25%
Aug-07-23 08:15AM	Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -7.21%
07:10AM	Aclaris: Q2 Earnings Snapshot (AP Finance)
07:00AM	Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-01-23 07:53AM	Investing in Aclaris Therapeutics (NASDAQ:ACRS) three years ago would have delivered you a 363% gain (Simply Wall St.)
Jul-06-23 08:19AM	Calliditas Therapeutics AB Sponsored ADR (CALT) Moves 12.8% Higher: Will This Strength Last? (Zacks)
Jun-26-23 10:15AM	2 Low-Priced Stocks That Could Make You Richer (Motley Fool)
Jun-13-23 06:30PM	Why Aclaris Therapeutics Topped the Market on Tuesday (Motley Fool)
07:01AM	Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202) (GlobeNewswire)
Jun-02-23 07:00AM	Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences (GlobeNewswire)
May-18-23 01:50PM	Top Pharmaceutical Stocks for Q2 2023 (Investopedia)
May-10-23 06:04AM	Aclaris Therapeutics First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-08-23 11:55PM	Q1 2023 Aclaris Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -6.46%
08:15AM	Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:08AM	Aclaris: Q1 Earnings Snapshot (AP Finance)
07:00AM	Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
May-05-23 06:49AM	What Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) P/S Is Not Telling You (Simply Wall St.)
May-02-23 07:01AM	Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023 (GlobeNewswire)
Apr-27-23 04:35AM	Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock? (Zacks)
Apr-24-23 02:37PM	3 Biotech Stocks to Sell Before Theyre 6 Feet Under (InvestorPlace)
Apr-04-23 07:40AM	Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation (Simply Wall St.)
Mar-27-23 07:00AM	Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire)
Mar-10-23 11:34AM	Lab Notes: Fox Chase Cancer Center researcher gets $1M grant; NRx raises funds (American City Business Journals)
Mar-06-23 03:59PM	As Focus Shifts From Hidradenitis Suppurativa, Analyst Seems Bullish On Aclaris (Benzinga) -44.68%
02:32PM	These 2 Biotech Stocks Made Big Monday Moves (Motley Fool)
01:03PM	Why Aclaris Therapeutics Stock Is Plunging Today (Benzinga)
11:50AM	Why Aclaris Therapeutics Is Crashing Today (Motley Fool)
07:00AM	Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa (GlobeNewswire)
Feb-23-23 08:35AM	Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-22-23 06:01AM	Investing in Aclaris Therapeutics (NASDAQ:ACRS) three years ago would have delivered you a 943% gain (Simply Wall St.)
Feb-09-23 04:01PM	Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-06-23 07:01AM	Aclaris Therapeutics Provides 2023 Outlook (GlobeNewswire) +8.67%
Nov-29-22 07:00AM	Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China (GlobeNewswire) -7.06%
Nov-26-22 01:39PM	Lab Notes: Biotech firm bioMerieux unveils new product for detecting spoiled wine (American City Business Journals)
Nov-22-22 04:01PM	Aclaris Therapeutics Announces Key Leadership Transitions (GlobeNewswire)
Nov-16-22 12:10PM	Aclaris Therapeutics Looks Promising on the Charts (TheStreet.com)

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Walker Neal	INTERIM CEO	Dec 04 '24	Option Exercise	1.52	118,840	180,637	1,501,973	Dec 06 04:15 PM
Mehra Anand	Director	Nov 19 '24	Buy	2.25	666,666	1,499,998	710,030	Nov 20 04:20 PM
Walker Neal	INTERIM PRESIDENT AND CEO	Aug 09 '24	Option Exercise	0.72	43,548	31,355	1,356,153	Aug 13 04:15 PM
Leonard Braden Michael	10% Owner	Aug 05 '24	Buy	1.24	206,025	256,357	14,250,000	Aug 05 03:57 PM
Leonard Braden Michael	10% Owner	Aug 02 '24	Buy	1.29	167,544	216,400	14,043,975	Aug 05 03:57 PM
Leonard Braden Michael	10% Owner	Jul 30 '24	Buy	1.30	173,730	226,370	13,776,421	Jul 31 04:10 PM
Leonard Braden Michael	10% Owner	Jul 31 '24	Buy	1.33	100,000	132,640	13,876,421	Jul 31 04:10 PM
Leonard Braden Michael	10% Owner	Jul 18 '24	Buy	1.30	130,317	169,555	13,578,286	Jul 22 04:03 PM
Leonard Braden Michael	10% Owner	Jul 22 '24	Buy	1.33	17,716	23,557	13,602,691	Jul 22 04:03 PM
Leonard Braden Michael	10% Owner	Jul 19 '24	Buy	1.30	6,689	8,696	13,584,975	Jul 22 04:03 PM
Leonard Braden Michael	10% Owner	Jul 03 '24	Buy	1.16	143,288	166,071	13,324,952	Jul 05 02:46 PM
Leonard Braden Michael	10% Owner	Jul 05 '24	Buy	1.15	123,017	141,334	13,447,969	Jul 05 02:46 PM
Leonard Braden Michael	10% Owner	Jul 02 '24	Buy	1.14	86,092	98,489	13,181,664	Jul 05 02:46 PM
Leonard Braden Michael	10% Owner	Jun 28 '24	Buy	1.12	1,201,000	1,348,559	12,988,134	Jul 01 01:39 PM
Leonard Braden Michael	10% Owner	Jun 27 '24	Buy	1.15	235,000	271,331	11,787,134	Jul 01 01:39 PM
Leonard Braden Michael	10% Owner	Jul 01 '24	Buy	1.14	107,434	122,185	13,095,572	Jul 01 01:39 PM
Leonard Braden Michael	10% Owner	Jun 14 '24	Buy	1.17	345,000	402,201	11,352,134	Jun 18 04:04 PM
Leonard Braden Michael	10% Owner	Jun 17 '24	Buy	1.13	150,000	169,500	11,502,134	Jun 18 04:04 PM
Leonard Braden Michael	10% Owner	Jun 18 '24	Buy	1.13	50,000	56,505	11,552,134	Jun 18 04:04 PM
Leonard Braden Michael	10% Owner	Jun 11 '24	Buy	1.08	1,000,000	1,080,000	10,395,934	Jun 13 06:04 PM
Leonard Braden Michael	10% Owner	Jun 13 '24	Buy	1.15	528,621	607,757	11,007,134	Jun 13 06:04 PM
Leonard Braden Michael	10% Owner	Jun 12 '24	Buy	1.14	82,579	94,140	10,478,513	Jun 13 06:04 PM
Powell Andrew Kenneth William	Director	Mar 01 '24	Buy	1.23	8,500	10,455	22,863	Mar 05 04:58 PM
Powell Andrew Kenneth William	Director	Mar 04 '24	Buy	1.25	6,000	7,500	28,863	Mar 05 04:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACRS

Aclaris Therapeutics Inc

Upgrade your FINVIZ experience